18 results
To determine the minimal biologic drug serum trough concentration required to maintain stable disease activity in patientswith moderate to severe chronic plaque psoriasis.
The objective is to assess the effect of adalimumab on selfconfidence and sexuality of patients with anogenital psoriasis.
To study the influence of anti-TNF therapy on the semen quality of IBD patients
Our main aim is to evaluate the effectiveness and cost-effectiveness of two tapering strategies:(i)DMARD tapering and (ii)anti-TNF tapering in RA patients with DMARD&anti-TNF(etanercept, adalimumab, certolizumab or golimumab) induced…
To assess the efficacy and safety of adalimumab for the induction of clinical remission in subjects with moderately to severely active ulcerative colitis.
Objectives1. Determine efficacy of adalimumab as the first biologic agent or after previous use of other anti-TNF blocking agent. Efficacy will be evaluated by means of the ASAS 20% response criteria.2. Determine the efficacy of adalimumab on…
The main objective is to evaluate whether adalimumab dose reduction using adalimumab serum measurements (TDM strategy) will minimize medical costs, compared to disease activity guided dose reduction in rheumatoid arthritis (RA) patients.
To assess non-inferiority of extending the adalimumab dosing interval, under strict disease monitoring in CD patients in sustained (>9months) clinical remission, compared to standard care.
The study will investigate in newly diagnosed CP-CML patients the efficacy of NIL frontline therapy vs IM followed by switch to NIL in the case of absence of optimal response as defined by the ELN criteria
Assessment of duration of MMR or better after stopping TKI therapy a second or third time in patients with at least three years prior TKI treatment comprising at least two years of nilotinib treatment and maintained stable MR4 for at least one year…
Primary: To assess the proportion of patients with intervention failure at 12 months after dose reduction, defined as patients who have restarted their initial dose due to (expected) loss of major molecular response.
The primary objective of this prospective study is to assess the clinical efficacy of the combination of adalimumab and surgery compared to adalimumab monotherapy after one year of treatment in adult patients with moderate to severe HS at the last…
Primary:To compare the efficacy of asciminib versus Investigator selected TKI with respect to the proportion of patients that are in Major Molecular Response at Week 48. To compare the efficacy of asciminib versus Investigator selected TKI, within…
The aim of this study is to compare the long-term efficacy and safety of periodic adalimumab as initial treatment in newly diagnosed CD patients compared to standard step-care with corticosteroid/budesonide as the initial treatment
To evaluate the efficacy of setmelanotide on changes in body weight.
Primary:• To evaluate the proportion of patients with obesity with genetic variants in a specific gene in the melanocortin-4 receptor (MC4R) pathway who achieve a clinically meaningful reduction in body weight in response to setmelanotide at the end…
Primary Objectives• To describe the anti-tumor activity and toxicity of commercially available, targeted anti-cancer drugs used for treatment of patients with an advanced solid tumor, multiple myeloma or non-Hodgkin lymphoma that harbours a genomic…
The purpose of this study is to determine the safety and efficacy of Nilotinib and Vildagliptin as combination therapy in optimal dosage. In addition, it is investigated whether the addition of Vildagliptin to Nilotinib treatment causes the…